We tested the ability of human monoclonal antibodies (immunoglobulin G1b12 [IgG1b12] and 19b) and CD4-based molecules (CD4-IgG2 and soluble CD4 [sCD4]) to neutralize human immunodeficiency virus type 1 directly from the plasma of seropositive donors in an ex vivo neutralization assay. IgG1b12 and CD4-IgG2, at concentrations from 1 to 25 g/ml, were found to be effective at reducing the HIV-1 titer in most plasma samples. When viruses recovered from plasma samples were expanded to produce virus stocks, no correlation between the neutralization sensitivities to IgG1b12 and CD4-IgG2 of the in vitro passaged stocks and those of the ex vivo neutralizations performed directly on the plasma was observed. These differences could be due to changes in neutralization sensitivity that occur after one passage of the virus in vitro, or they could be related to the presence of complement or antibodies in the plasma. Furthermore, differences in expression of adhesion molecules on plasma-derived and phytohemagglutinin-activated peripheral blood mononuclear cell-derived viruses could be involved. These studies suggest that IgG1b12 and CD4-IgG2 have broad and potent neutralizing activity in both in vitro and ex vivo neutralization assays and should be considered for use as potential immunoprophylactic or therapeutic agents.
Recombinant soluble CD4 (sCD4), which represents the extracellular domain of the cell surface receptor for human immunodeficiency virus type 1 (HIV-1), was initially demonstrated to effectively block infection of laboratory strains of HIV-1 in vitro (11, 14, 17, 18, 23, 36, 40) . However, it was later shown that primary isolates of HIV-1 are relatively resistant to neutralization by sCD4 (3, 10, 23) and that the sensitivity of primary HIV-1 isolates could be increased by repeated passage in vitro (10, 23) . The clinical relevance of these findings became apparent when it was demonstrated that, at a concentration capable of neutralizing laboratory-adapted strains of HIV-1, sCD4 was ineffective at neutralizing HIV-1 directly from samples of patient plasma in an ex vivo format (10) . This finding was correlated with relative ineffectiveness in therapeutic trials (9, 10) . It has now been shown that primary HIV-1 isolates are relatively resistant not only to neutralization by sCD4 (3, 10, 23, 27, 32) but also to monoclonal antibodies (24, 25) and other CD4-based molecules (18, 24) , compared with laboratory-adapted strains of HIV-1, a finding that has caused concern among those charged with developing immunotherapeutics and vaccines against HIV-1 (9).
Despite the relative resistance of primary HIV-1 isolates to neutralization, recent studies have shown that primary HIV-1 isolates can be neutralized in vitro by certain monoclonal antibodies, CD4-based molecules, and the sera of long-term nonprogressors from HIV-1 infection (1, 7, 8, 41) . Most of the potent monoclonal antibodies, however, have not been tested for their ability to neutralize HIV-1 directly from plasma, as was done with sCD4. We therefore sought to study the ability of these newer molecules to neutralize HIV-1 directly from patient plasma samples in an ex vivo assay. The antibody products we chose to study were immunoglobulin G1b12 (IgG1b12), a human monoclonal antibody produced from a combinatorial phage display library (7, 33) , and CD4-IgG2, a tetrameric human antibody prepared from a human IgG2 with replacement of each heavy-and light-chain variable region by the first and second domains of human CD4 (1) . Both IgG1b12 and CD4-IgG2 recognize discontinuous epitopes overlapping the CD4-binding site (CD4-BS) on HIV-1 gp120 (1, 7, 33) and have been shown to effectively neutralize primary HIV-1 isolates in standard in vitro assays (1, 7) . In our studies, controls included sCD4 and 19b, a human V3-specific antibody that recognizes determinants within the third variable region of HIV-1 gp120 (28, 35) . Monoclonal antibody 19b was produced by B-cell transformation and cloning and has limited activity against primary isolates of HIV-1 (24, 41) .
We first assessed the ability of IgG1b12, CD4-IgG2, and sCD4 to neutralize four distinct isolates of HIV-1 in a standard in vitro neutralization assay. The four HIV-1 isolates included a virus adapted to grow in transformed T-cell lines (LAI), a molecularly cloned isolate (JR-CSF) that demonstrates many of the characteristics of a primary HIV-1 isolate and will not grow in transformed T-cell lines (20) , and two primary HIV-1 isolates (AD6 and WH91-330) that have been passaged twice in mitogen-stimulated peripheral blood mononuclear cells (PBMC) and will not grow in transformed T-cell lines (19, 42) . IgG1b12, CD4-IgG2, and sCD4 were tested at concentrations from 0.006 to 100 g/ml for their ability to neutralize a fixed inoculum of these viruses (200 50% tissue culture infective doses [TCID 50 ]) on phytohemagglutinin (PHA)-stimulated PBMC by previously described methods (8, 24, 41) . Viral p24 antigen was measured by enzyme immunoassay (Abbott Laboratory, Abbott Park, Ill.) on days 4 to 7, and neutralization curves were generated (Fig. 1) .
Consistent with previous observations (1, 24) , sCD4 effectively neutralized LAI and JR-CSF ( Fig. 1 ) with 50% inhibitory doses (ID 50 ) and ID 90 of 0.024 and 0.39 g/ml for LAI and 0.8 and 5.5 g/ml for JR-CSF, respectively. However, sCD4 was not effective in neutralizing WH91-330 (Ͻ20% reduction in p24 production at 100 g/ml) but was moderately effective in neutralizing the other primary isolate AD6, with an ID 50 of 9 g/ml and an ID 90 of 90 g/ml. Neither LAI nor JR-CSF showed significant differences in neutralization sensitivity to sCD4, IgG1b12, and CD4-IgG2. In contrast, primary isolates AD6 and WH91-330 were more sensitive to neutralization by IgG1b12 and CD4-IgG2 than by sCD4. While there was some loss in neutralization sensitivity to IgG1b12 and CD4-IgG2 when moving from laboratory strains to primary isolates, the greatest loss in sensitivity was to sCD4 (Fig. 1) . These results confirm that primary isolates AD6 and WH91-330 are relatively resistant to neutralization, even by IgG1b12 and CD4-IgG2, but to a much lesser degree than they are resistant to neutralization by sCD4.
We next sought to test the ability of IgG1b12 and CD4-IgG2 to neutralize viruses that had not previously been subjected to passage, and possible selection, in vitro, by using a previously published method (10) . All plasma samples used in this study were drawn from HIV-1-infected patients in the New York metropolitan area. Briefly, sCD4, 19b, IgG1b12, or CD4-IgG2 (final concentration, 25 g/ml) was added to 24-well plates containing serial fivefold dilutions of HIV-1-infected plasma. The mixture was incubated with 2 ϫ 10 6 PHA-stimulated PBMC from an uninfected donor. After 24 h, the cultures were washed extensively and cultured for 14 days. Viral replication was measured by the expression of p24 antigen in the culture supernatants by using a commercial enzyme immunoassay (Abbott) on days 7 and 14. An end-point titer of infectious HIV-1 in the presence or in the absence of added reagent was calculated (10, 16) . A culture was considered positive if the p24 value was above 50 pg/ml.
Plasma samples from six donors were used to perform ex vivo neutralization assays. These HIV-1-infected plasma samples were selected on the basis of having an initial infectious titer of at least 250 TCID 50 /ml and therefore were derived from patients in the later stages of HIV-1 infection. The infectious titer of HIV-1 in the plasma samples in the presence or in the absence of each monoclonal product is shown in Fig.  2 . With this assay we were unable to reproducibly measure a fivefold or smaller reduction in infectious titer within any given plasma sample (data not shown), and we therefore defined effective neutralization as a greater-than-fivefold decrease in viral titer in a plasma sample. Both IgG1b12 and CD4-IgG2 neutralized HIV-1 in 5 of 6 plasma samples (Fig. 2) . The degree of neutralization ranged from a 25-to a 625-fold reduction in the original infectious titer. In comparison, sCD4 and 19b, when used at the same concentration, neutralized HIV-1 in 0 of 4 and 2 of 6 plasma samples, respectively. Therefore, IgG1b12 and CD4-IgG2 appear to be more effective in neutralizing plasma HIV-1 isolates in ex vivo neutral- VOL. 70, 1996 NOTES 2587 ization assays than are sCD4 and 19b. It is also important to note that viruses within one of the six plasma samples were resistant to neutralization by IgG1b12 but sensitive to CD4-IgG2 (patient no. 2), while viruses within another plasma sample (patient no. 14) were resistant to CD4-IgG2 but sensitive to IgG1b12. This result is not unexpected, considering that the two antibody preparations recognize distinct, though overlapping, sites on gp120 and that virus isolates that are resistant to one, the other, or both products have been previously described (41) . The ex vivo neutralization assay involves serially diluting patient plasma samples in 24-well tissue culture plates. Therefore, each well contains not only a different infectious inoculum of HIV-1 but also a different concentration of human plasma. To rule out the possibility that these different plasma concentrations could affect the ex vivo neutralization results, we tested the ability of IgG1b12 and CD4-IgG2 to neutralize virus present in four of the previous plasma samples when the plasma was diluted in culture medium or normal human plasma. Under the latter conditions, the concentration of human plasma was kept constant in all wells. As shown in Fig. 3 , the use of plasma as a diluent did not affect the neutralization results by more than fivefold, indicating that high or low concentrations of plasma do not significantly affect the ex vivo neutralization assays. In addition, the results in these assays were similar to those shown in Fig. 1 , indicating the reproducibility (within a fivefold difference) of the assays.
We next tested IgG1b12 and CD4-IgG2 at 1, 5, and 25 g/ml in ex vivo assays. Results from seven different plasma samples are shown in Fig. 4 . Viruses in some of the plasma samples (patients no. 301, 404, and 17) were sensitive to these antibody products at 1 g/ml, while viruses in other plasma samples (patients no. 410 and 20) were sensitive only at 25 g/ml. In general, however, it is remarkable how similar the activities of these two products against viruses in these seven plasma samples were. This would not be apparent, however, if only one concentration of antibody were tested (i.e., 25 g/ml on plasma from patient no. 20). These results indicate that, in contrast to previous studies with sCD4 (10) , effective ex vivo neutralization of virus in most plasma samples can be achieved with between 1 and 25 g of IgG1b12 or CD4-IgG2 per ml.
To determine if passage of virus in plasma through PHAactivated PBMC would alter the neutralization sensitivity, in vitro neutralization assays against virus passaged once in PHAactivated PBMC (P1 isolates) recovered from six HIV-1-infected plasma samples were performed. Both reagents were utilized at graded concentrations from 0.001 to 100 g/ml. In general, both IgG1b12 and CD4-IgG2 were active against most of the P1 isolates; the ID 90 were Ͻ1 g/ml for virus from patient no. 14, 1 to 10 g/ml for patients no. 2 and 3, and 10 to 100 g/ml for patients no. 17 and 20. Only virus from patient no. 9 could not be neutralized 90% or more by 100 g of IgG1b12 or CD4-IgG2 per ml.
No correlation between the neutralization sensitivities of IgG1b12 and CD4-IgG2 in ex vivo assays and those in in vitro neutralization assays performed on P1 isolates from those plasma samples (Fig. 2, 4 , and 5) was observed. As shown in Fig. 2 , HIV-1 in the plasma from patient no. 2 was potently neutralized ex vivo by CD4-IgG2 (Ͼ625-fold at 25 g/ml) and not by IgG1b12 (at the same concentration). However, the P1 isolate generated from that plasma was comparably neutralized in vitro by both reagents (ID 50 and ID 90 , 0.1 and 3.12 g/ml, respectively [ Fig. 5]) . A further example is provided by a plasma sample from patient no. 14 that was not significantly neutralized in the ex vivo assay by CD4-IgG2 but was neutral- ized by IgG1b12 (5-and 625-fold reduction in infectivity at 25 g/ml, respectively [ Fig. 2] ), yet the corresponding P1 isolate was equally neutralized in vitro by both reagents (Ͼ95% neutralization at 25 g/ml). Therefore, the viruses best neutralized in vitro were not necessarily derived from the plasma samples with the best ex vivo neutralization profiles. Much of this discrepancy may relate to selection of viruses upon passage in PHA-stimulated PBMC. The biphasic nature of many of the in vitro neutralization curves (IgG1b12 curve for patient no. 14, for instance [ Fig. 5]) indicates that some of the P1 isolates contain mixtures of viruses with different sensitivities to IgG1b12 and CD4-IgG2.
Our results indicate that both human monoclonal antibody IgG1b12 and the CD4-based molecule CD4-IgG2 effectively neutralize HIV-1 directly from the plasma of seropositive donors in an ex vivo neutralization assay. Additionally, IgG1b12 and CD4-IgG2 effectively neutralize T-cell line-adapted strains and primary isolates of HIV-1. However, when viruses recovered from plasma samples were expanded in PBMC to produce virus stocks, the in vitro neutralization sensitivity of those plasma-derived stocks could not be predicted by the previous ex vivo neutralization assays.
Both IgG1b12 and CD4-IgG2 interact with the discontinuous CD4-BS on gp120 (1, 4, 33) . In order to maintain the ability to bind CD4, certain as yet undefined structural features of this epitopic region remain conserved between virus isolates (29) . It is therefore logical that the two broadly reactive neutralizing antibody-based products described here interact with this region. Since gp120 exists in multimeric form on the surface of the virus (6, 12, 34) , the structural constraints upon the CD4-BS may also be apparent in the multimeric structure of the surface protein. The structural and functional differences in gp120s from different isolates of HIV-1 may not be measurable in assays based upon the monomeric form of this glycoprotein. Indeed, it has been shown that the CD4-BS of primary HIV-1 isolates from diverse geographic clades are conserved (26) and accessible to monoclonal antibodies when measured on gp120 monomers. The CD4-BS as expressed on multimeric gp120-gp41 complexes may therefore be significantly different from the domain as expressed on gp120 monomers (22, 34, 39) . Assaying the neutralization sensitivity of unpassaged virus to monoclonal antibodies may be one method for measuring the functional differences in multimeric gp120.
Many other antibodies that interact with the CD4-BS on gp120 have failed to demonstrate the broad and potent neutralization of primary isolates of HIV-1 as demonstrated by IgG1b12 and CD4-IgG2 (24) . This fact can probably be explained by the fact that most of those products bound well to monomeric gp120 but were not specifically capable of binding to multimeric gp120. It has now been shown that virus neutralization correlates broadly with monoclonal antibody binding to the multimeric form of gp120 (34, 39) . IgG1b12 has been shown to bind well to multimeric gp120 (34) . This observation FIG. 4 . Ex vivo neutralization at various concentrations of CD4-IgG2 and IgG1b12. CD4-IgG2 (ᮀ) and IgG1b12 (F), at 1, 5, and 25 g/ml, were incubated with serial dilutions of plasma samples from seven HIV-1-infected patients. Viral replication was measured by the expression of p24 antigen in the culture supernatant on days 7 and 14, and an end-point titer was calculated.
VOL. 70, 1996 NOTES 2589 probably explains its broad ability to neutralize primary HIV-1 isolates (7, 41) . Two observations make it unlikely that V3-specific antibodies (like 19b) will have the broad and potent neutralizing activity observed with IgG1b12 and CD4-IgG2. First, it is unlikely that a monoclonal product will overcome the amino acid sequence heterogeneity in this region (30) . Second, while the V3 region may be well exposed on both oligomeric and monomeric forms of gp120 from T-cell line-adapted viruses, this region is shielded from monoclonal antibodies on the surface of primary isolates of HIV-1 (5) .
We have demonstrated that there are differences in virus sensitivity to monoclonal products between ex vivo and in vitro neutralization assays. There are several potential explanations for this finding. During the process of expanding a P1 virus stock, selection of minor variants within the original sample may occur (21, 38) . In this case, the virus species within the P1 stock will no longer accurately reflect the virus quasispecies present in the initial plasma sample. Since this expansion is performed in the absence of antibody-mediated immune pressure, it is not unreasonable to assume that a neutralizationsensitive virus, which would have been somewhat suppressed in vivo by the antibodies present in plasma, might rapidly grow to be the dominant species in the P1 isolate.
Factors other than selection of viral variants through in vitro passage may also be involved in the differences between the results of ex vivo and in vivo neutralization assays. The ex vivo assays are performed in the presence of plasma. The monoclonal products will therefore be affected by prebound antibodies which may compete for epitopes on the viruses. In addition, the plasma samples are not heated, so complement remains active. The ex vivo assay may therefore also measure antibody-dependent complement-mediated neutralization that is not measured in the in vitro assay (37) . Finally, since the P1 isolates are expanded in PHA-activated PBMC, they probably express higher levels of adhesion and class II molecules than do viruses in plasma (2, 13, 15, 31) . This may affect their sensitivity to neutralization. The heterogeneity of gp120 among HIV-1 isolates and the lack of sensitivity of primary isolates of HIV-1 to neutralization have been major obstacles to vaccine development and the use of antibody-based therapeutic or prophylactic strategies (9, 10) . The breadth and potency of CD4-IgG2 and IgG1b12 in neutralizing HIV-1 directly from plasma make them good candidates for future studies of HIV-1 prophylaxis in animal studies and in human trials.
